{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:16:12Z","timestamp":1787314572562,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020992","name":"Caisse nationale de l'Assurance Maladie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40259-026-00768-y","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:27:31Z","timestamp":1772540851000},"page":"349-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-6299","authenticated-orcid":false,"given":"Allison","family":"Singier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-6631","authenticated-orcid":false,"given":"St\u00e9phane","family":"Vignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Desplas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-4217","authenticated-orcid":false,"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-8280","authenticated-orcid":false,"given":"Nadia","family":"Haddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"768_CR1","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France 2024."},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12\u201339. https:\/\/doi.org\/10.1136\/ijgc-2020-002230.","journal-title":"Int J Gynecol Cancer"},{"key":"768_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/J.YGYNO.2016.10.025","volume":"144","author":"S Bendifallah","year":"2017","unstructured":"Bendifallah S, Ouldamer L, Lavoue V, et al. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO consensus conference risk groups: results from the FRANCOGYN study group. Gynecol Oncol. 2017;144:107\u201312. https:\/\/doi.org\/10.1016\/J.YGYNO.2016.10.025.","journal-title":"Gynecol Oncol"},{"key":"768_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2023.41165","volume":"6","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Berton D, Curigliano G, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open. 2023;6:e2341165. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2023.41165.","journal-title":"JAMA Netw Open"},{"key":"768_CR5","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/nejmoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145\u201358. https:\/\/doi.org\/10.1056\/nejmoa2216334.","journal-title":"N Engl J Med"},{"key":"768_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/J.BULCAN.2023.06.009","volume":"110","author":"M Rodrigues","year":"2023","unstructured":"Rodrigues M, Eberst L, Follana P, et al. Real-world dostarlimab use in advanced\/recurrent endometrial cancer in France. Bull Cancer. 2023;110:1041\u201350. https:\/\/doi.org\/10.1016\/J.BULCAN.2023.06.009.","journal-title":"Bull Cancer"},{"key":"768_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101903","volume":"35","author":"A Gallego","year":"2025","unstructured":"Gallego A, Madariaga A, Est\u00e9vez-Garc\u00eda P, et al. An ambispective, real-world multi-center study of DOstarlimab in patients with recurrent or advanced DNA mismatch repair deficient\/microsatellite instability-high endometrial cancer (GEICO 120-R\/DORA study). Int J Gynecol Cancer. 2025;35:101903. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101903.","journal-title":"Int J Gynecol Cancer"},{"key":"768_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","volume":"58","author":"P Tuppin","year":"2010","unstructured":"Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286\u201390. https:\/\/doi.org\/10.1016\/j.respe.2010.04.005.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"768_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/J.ESMOOP.2024.104083","volume":"9","author":"H Jourdain","year":"2024","unstructured":"Jourdain H, Meglio AD, Mansouri I, et al. Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study. ESMO Open. 2024;9:104083. https:\/\/doi.org\/10.1016\/J.ESMOOP.2024.104083.","journal-title":"ESMO Open"},{"key":"768_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey G, Jougla E, Fouillet A, et al. Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:1\u201312. https:\/\/doi.org\/10.1186\/1471-2458-9-33.","journal-title":"BMC Public Health"},{"key":"768_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100970","volume":"43","author":"A Rousseau","year":"2024","unstructured":"Rousseau A, Michiels S, Simon-Tillaux N, et al. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg Health Eur. 2024;43:100970. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100970.","journal-title":"Lancet Reg Health Eur"},{"key":"768_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-05667-8","volume":"20","author":"A Janah","year":"2020","unstructured":"Janah A, Le Bihan-Benjamin C, Mancini J, et al. Access to inpatient palliative care among cancer patients in France: an analysis based on the national cancer cohort. BMC Health Serv Res. 2020;20:798. https:\/\/doi.org\/10.1186\/s12913-020-05667-8.","journal-title":"BMC Health Serv Res"},{"key":"768_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","volume":"60","author":"A Rachas","year":"2022","unstructured":"Rachas A, Gastaldi-M\u00e9nager C, Denis P, et al. The economic burden of disease in France from the National Health Insurance Perspective The Healthcare Expenditures and Conditions Mapping Used and the Public Health Act. Med Care. 2022;60:655\u201364. https:\/\/doi.org\/10.1097\/MLR.0000000000001745.","journal-title":"Med Care"},{"key":"768_CR14","unstructured":"R Core Team. R: a Language and environment for statistical computing. 2024."},{"key":"768_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag; 2016."},{"key":"768_CR16","unstructured":"Therneau TM. A Package for survival analysis in R. 2024."},{"key":"768_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00359-x","author":"J Wallis","year":"2025","unstructured":"Wallis J, Luhar S, Tunaru F, et al. A real \u2011 world retrospective observational study of patients with advanced \/ recurrent endometrial cancer across England. Oncol Ther. 2025. https:\/\/doi.org\/10.1007\/s40487-025-00359-x.","journal-title":"Oncol Ther"},{"key":"768_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.YGYNO.2024.10.022","volume":"192","author":"MA Powell","year":"2025","unstructured":"Powell MA, Cibula D, O\u2019Malley DM, et al. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY). Gynecol Oncol. 2025;192:40\u20139. https:\/\/doi.org\/10.1016\/J.YGYNO.2024.10.022.","journal-title":"Gynecol Oncol"},{"key":"768_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101935","author":"DM Chase","year":"2025","unstructured":"Chase DM, Herrstedt J, Miller EM, et al. Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel. Int J Gynecol Cancer. 2025. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101935.","journal-title":"Int J Gynecol Cancer"},{"key":"768_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e17630","author":"SF Haddad","year":"2025","unstructured":"Haddad SF, Adcock B, Dhakal A, et al. Prognostic factors and treatment outcomes in stage IV endometrial carcinoma: a 13-year single center experience. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e17630.","journal-title":"J Clin Oncol"},{"key":"768_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamanetworkopen.2025.29225","volume":"8","author":"A Rousseau","year":"2025","unstructured":"Rousseau A, Simon-tillaux N, Michiels S, et al. Concomitant comedications and survival with first-line pembrolizumab in advanced non\u2013small-cell lung cancer. JAMA Netw Open. 2025;8:1\u201314. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.29225.","journal-title":"JAMA Netw Open"},{"key":"768_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115560","author":"E Gobbini","year":"2025","unstructured":"Gobbini E, Langlais A, Missy P, et al. Morphine and metformin impact immunotherapy benefit in patients with NSCLC: results of the real-world study IFCT-1502 CLINIVO-SNDS. Eur J Cancer. 2025. https:\/\/doi.org\/10.1016\/j.ejca.2025.115560.","journal-title":"Eur J Cancer"},{"key":"768_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563\u201380. https:\/\/doi.org\/10.1038\/s41571-019-0218-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"768_CR24","unstructured":"Committee for Medicinal Products for Human Use (CHMP) - European Medicines Agency (EMA). Annex I Summary of product characteristics - Dostarlimab (Jemperli). 2021."},{"key":"768_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227256","volume":"15","author":"C Huang Bartlett","year":"2020","unstructured":"Huang Bartlett C, Mardekian J, Cotter MJ, et al. Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS ONE. 2020;15:e0227256. https:\/\/doi.org\/10.1371\/journal.pone.0227256.","journal-title":"PLoS ONE"}],"updated-by":[{"DOI":"10.1007\/s40259-026-00778-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00768-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00768-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00768-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:46:52Z","timestamp":1780552012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00768-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00768-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"6 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the text \u2018dMMR endometrial cancer\u2019 should\nhave read \u2018endometrial cancer\u2019 in all instances and few other corrections updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40259-026-00778-w","URL":"https:\/\/doi.org\/10.1007\/s40259-026-00778-w","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Allison Singier, St\u00e9phane Vignot, David Desplas, Mahmoud Zureik, and Nadia Haddy declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted in compliance with the French regulations on access and processing of personal data from the SNDS. EPI-PHARE has permanent regulatory access to the data from the French National Health Data System (SNDS) via its constitutive bodies ANSM and CNAM, in application of the provisions of the French Decree No. 2016-1871 of 26 December 2016 relating to the processing of personal data called the \u201cNational Health Data System\u201d, the French law articles Art. R. 1461-1316 and R. 1461-1417 from the French Public Health Code and the French Data Protection Authority (CNIL) decision CNIL-2016-316.18. In accordance with the permanent regulatory access granted to EPI-PHARE via ANSM and CNAM, this work did not require any specific opinion from the French Ethical and Scientific Committee for Research, Studies, and Evaluations health (CESREES) nor approval from the CNIL. All requests in the database were made by duly authorized people. The study was registered on the study register of EPI-PHARE concerning studies from SNDS data under the reference T-2025-05-586. No informed consent is required for studies based on the SNDS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"In accordance with data protection legislation and the French regulation, the authors are not allowed to release or make public the data from the SNDS. However, any person or structure, public or private, for-profit or nonprofit, is able to access SNDS data in order to carry out a study, research or an evaluation in the public interest, upon authorization from the French Data Protection Office (CNIL), via the French Health Data Hub (\n                      \n                      ).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AS: conceptualization, methodology, formal analysis, validation, visualization, writing\u2014original draft, writing\u2014review & editing; SV: conceptualization, validation, writing\u2014review & editing; DD: conceptualization, data curation, validation, writing\u2014review & editing; MZ: conceptualization, funding acquisition, methodology, supervision, validation, writing\u2014review & editing; NH: conceptualization, methodology, supervision, validation, writing\u2014review & editing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}